PepGen is a biotechnology company focused on developing advanced nucleic acid therapeutics using its proprietary peptide technology. The company collaborates with researchers and medical institutions to address complex medical conditions, including Duchenne and Becker muscular dystrophy. Operating primarily in the biopharmaceutical market, PepGen serves healthcare providers and research organizations. Its business model involves both independent and partnered development pathways, generating revenue through research collaborations, licensing agreements, and potential future sales of therapeutic products. The company aims to revolutionize the delivery of nucleic acid-based drugs, enhancing their efficacy and reach.

Keywords: peptide technology, nucleic acid therapeutics, biotechnology, drug delivery, Duchenne muscular dystrophy, Becker muscular dystrophy, biopharmaceutical, research collaboration, licensing agreements, therapeutic products.